Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
AuthorsTrainer, Peter J
AffiliationChristie Hospital, Manchester, UK. email@example.com
MetadataShow full item record
AbstractPegvisomant is a GH receptor antagonist and a new agent for the medical management of acromegaly. The clinical efficacy and safety of pegvisomant in the treatment of active acromegaly were demonstrated in a 12-week, placebo-controlled trial of 112 patients. After a washout period, patients were randomized to a fixed dose of pegvisomant (10, 15 or 20 mg/day) or placebo given by sc injection. Serum IGF-I levels were within the normal age-adjusted reference range in 54, 81 and 89% of patients in the 10-, 15- and 20-mg/day groups, respectively. The decrease in serum IGF-I levels was accompanied by considerable improvement in the signs and symptoms of active acromegaly. This efficacy profile was maintained in a long-term continuation trial, with normalization of serum IGF-I at 12 months occurring in 97% of patients. Pegvisomant has been well tolerated with an adverse event profile similar to placebo. Two patients had elevations in liver function tests that resolved after discontinuing treatment with pegvisomant. During treatment with pegvisomant, liver function tests should be monitored on a regular basis. Two patients had an increase in pituitary tumor volume during pegvisomant therapy; however, the relationship to pegvisomant therapy was not clear. In 131 patients treated for at least 6 months, there was no increase in mean tumor volume, regardless of whether they underwent previous radiotherapy. Pegvisomant is an effective new treatment for the management of patients with acromegaly. Longer-term data are needed to confirm the safety profile that has been demonstrated in studies up to 18 months.
CitationLessons from 6 years of GH receptor antagonist therapy for acromegaly. 2003, 26 (10 Suppl):44-52 J. Endocrinol. Invest.
JournalJournal of Endocrinological Investigation
- The German ACROSTUDY: past and present.
- Authors: Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study.
- Issue date: 2009 Nov
- Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
- Authors: Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators.
- Issue date: 2007 Jan
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
- Authors: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
- Issue date: 2006 Mar
- Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
- Authors: Shimatsu A, Nagashima M, Hashigaki S, Ohki N, Chihara K
- Issue date: 2016 Apr 25
- [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
- Authors: Zgliczyński W, Zdunowski P
- Issue date: 2007 Sep-Oct